Key statistics
On Monday, Editas Medicine Inc (8EM:FRA) closed at 3.02, 4.69% above its 52-week low of 2.88, set on Oct 03, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.02 |
---|---|
High | 3.02 |
Low | 3.02 |
Bid | -- |
Offer | -- |
Previous close | 2.92 |
Average volume | 1.72k |
---|---|
Shares outstanding | 82.48m |
Free float | 82.21m |
P/E (TTM) | -- |
Market cap | 278.77m USD |
EPS (TTM) | -2.36 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 07:00 BST.
More ▼
Announcements
- Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
- Editas Medicine to Participate in Upcoming Investor Conferences
- Editas Medicine Announces Second Quarter 2024 Results and Business Updates
- Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
- Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
- Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
- Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
- Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
- Editas Medicine Announces First Quarter 2024 Results and Business Updates
- Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
More ▼